These innovative agents represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in reducing blood glucose levels. https://jesseosqy210039.vblogetin.com/45133433/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide